Table 2.
Univariate analysis and multivariate analysis for predictors of overall survival
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | CI | p | HR | CI | p | |
| Age | 1.782 | 1.077–2.947 | 0.024 | 1.637 | 0.769–3.483 | 0.303 |
| Tumor size | 0.389 | 0.177–0.855 | 0.019 | 1.404 | 0.762–2.587 | 0.245 |
| N classification | 0.160 | 0.079–0.324 | 0.000* | 0.192 | 0.092–0.400 | 0.000* |
| Grading | 0.554 | 0.287–1.271 | 0.184 | 0.757 | 0.347–1.652 | 0.484 |
| ER status | 0.413 | 0.187–0.540 | 0.000* | 0.345 | 0.155–0.768 | 0.496 |
| PR status | 0.457 | 0.270–0.737 | 0.002 | 1.302 | 0.609–2.783 | 0.006 |
| HER-2 status | 1.013 | 0.615–1.287 | 0.018 | 1.914 | 1.253–3.724 | 0.021 |
| Staging | 1.422 | 1.379–3.185 | 0.068 | 1.687 | 0.914–2.849 | 0.083 |
| TMED3 | 3.059 | 1.763–5.309 | 0.000* | 1.852 | 1.013–3.387 | 0.017 |
Variables: age, > 48 vs. ≤ 48; tumor size, < 2 cm vs. ≥ 2 cm, LNM, negative vs. positive, Chemotherapy, yes vs. no; ER status, positive vs. negative; PR status, positive vs. negative; HER-2 status, positive vs. negative; Ki-67 status, positive vs. negative; TMED3, high expression vs. low expression; Cox proportional hazards model; “*” represent “p < 0.001”
HR hazard ratio, CI confidence interval, TMED3 transmembrane P24 trafficking protein 3, ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor-2, Ki-67 protein encoded by the MKI67 gene